The Activator Protein-1 (AP-1) complex is a dimeric transcription factor composed of fos and jun proteins that regulates cellular growth and dierentiation. We previously demonstrated a reduction in basal AP-1 transcriptional activity associated with the malignant transformation of human bronchial epithelial (HBE) cells that was, in part, a consequence of decreased c-fos expression. In this study, we investigated the mechanisms underlying the reduction in c-fos expression associated with the malignant transformation of HBE cells. c-Fos gene transcription was lower in tumorigenic HBE cells than in normal HBE cells, and the reduction in transcription involved c-fos gene promoter elements from 7327 to +40. DNaseI footprinting and band shift analyses of motifs within this c-fos promoter region, including a cyclic AMP response element (CRE), serum response element (SRE), sis-inducible element (SIE), and a YY1 site, revealed that binding to these motifs was greater in tumorigenic HBE cells than in normal HBE cells. Site-directed mutagenesis of the CRE partially relieved the repression of c-fos promoter activity in tumorigenic HBE cells. Further, the activity of the Jun N-terminal Kinase (JNK)-dependent pathway, which was a positive regulator of the c-fos promoter, was greater in normal HBE cells than in tumorigenic HBE cells. These ®ndings demonstrate a transcriptionally-mediated suppression of c-fos gene expression associated with the malignant transformation of HBE cells. The decreased activity of the c-fos promoter in tumorigenic 1170I cells appeared to involve suppression through a CRE site and reduced activation by JNK-dependent pathways.
Introduction
The AP-1 transcription factor is composed of protein products of the fos and jun gene families, which include c-fos, fra-1, fra-2, fos-B, c-jun, jun-B and jun-D (Bohmann et al., 1987; Chiu et al., 1988; Rauscher et al., 1988) . AP-1 has been implicated in the eects of a number of agents, including serum, peptide growth factors, ultraviolet light and phorbol esters, on cellular growth and dierentiation Curran et al., 1985; Buscher et al., 1988) . These agents regulate the expression of certain fos and jun gene family members through speci®c DNA elements in gene promoters. The c-fos gene promoter contains a serum response element (SRE) that binds a ternary complex containing the serum response factor (SRF), Elk-1, and SRF Accessory Proteins (SAP)-1 and -2 (Norman et al., 1988; Price et al., 1995) . Adjacent to the SRE is an ETS motif which is necessary for DNA-binding by the ternary complex (Karim et al., 1990) . Adjoining the SRE is an AP-1 site (TRE), which appears to be constitutively occupied in vivo (Herrera et al., 1989) . A sis-inducible element (SIE), which binds cytokine-and growth factor-regulated members of the Signal Transduction and Transcription (STAT) protein family, is located 5' of these regulatory regions (Hayes et al., 1987) . A cyclic AMP response element (CRE), which binds members of the activating transcription factor/CRE-binding protein (ATF/ CREB) transcription factor family, is located 3' of the SRE; this CRE interacts functionally with an adjacent binding site for the YY1 transcription factor (Natesan and Gilman, 1993) .
The response elements in the c-fos promoter are regulated by a variety of signal transduction pathways. Their complex nature is exempli®ed by pathways regulating SRE activity. Ternary complex transcriptional activity is activated by mitogen activated protein (MAP) kinases, including the p42 and p44 (extracellular signal-regulated kinase; ERK) kinases, the cJun N-terminal kinases (JNK)/SAP kinases, and the p38 kinase (Karin, 1995; Marshall, 1995) . MAP kinase pathway activation phosphorylates Elk-1, leading to increased Elk-1 DNA binding, ternary complex formation, and activation of the c-fos promoter (Marais et al., 1993; Whitmarsh et al., 1995; Janknecht and Hunter, 1997; Cavigelli et al., 1995; Gille et al., 1995) . Binding of the ternary complex to the SRE can stimulate or inhibit c-fos promoter activity, depending on the composition and phosphorylation state of the ternary complex (Galvin and Shi, 1997; Zinck et al., 1993) . The regulatory role of c-fos promoter elements is further complicated by cooperative eects; indeed, studies with c-fos transgenes suggest that upstream elements cooperate to activate the c-fos promoter, and deletion of any element abolishes c-fos promoter activity (Robertson et al., 1995) .
Using a lung carcinogenesis model consisting of normal, immortalized, and tumorigenic human bronchial epithelial (HBE) cells, we previously demonstrated a reduction in basal AP-1 transcriptional activity associated with malignant transformation that was, in part, a consequence of decrease c-fos expression (Lee et al., 1997) . In this model, the immortalized 1198 and tumorigenic 1170I cells grow in media that contains 3% fetal calf serum, while the normal human bronchial epithelial (HBE) and immortalized 1799 cells grow in serum-free media. We previously chose to standardize the growth conditions of these cells by removing serum from the immortalized 1198 and tumorigenic 1170I cells, providing growth conditions identical to that of normal HBE and immortalized 1799 cells. Immortalized 1198 and tumorigenic 1170I cells can proliferate at a reduced rate in the absence of serum for 3 ± 4 days. At 24 and 48 h after removal of serum, AP-1 transcriptional activity was unchanged from that of cells grown in the presence of serum (Lee et al., 1997) . This result suggests that the presence of serum in immortalized 1198 and tumorigenic 1170I cells did not account for the reduced AP-1 transcriptional activity and c-fos expression in these cells. Previous studies reveal a reduction in c-fos expression associated with malignant transformation to be paradoxical; c-fos has oncogenic properties and increases in abundance with malignant progression in a skin carcinogenesis model (Saez et al., 1995) . Further, a reduction in c-fos levels has been associated with a loss of proliferative potential Curran et al., 1985; Talmage and Listerud, 1994) , which is not a characteristic of the tumorigenic HBE cells in this study. Because a reduction in c-fos in association with malignant transformation is discordant with known patterns of c-fos expression, we sought to examine the mechanisms that underlie this event. We observed that the reduction in c-fos mRNA levels was transcriptionally-mediated and involved elements in the c-fos promoter from 7327 to +40. Within this region, binding at the SRE, SIE, CRE and a YY1 site was greater in tumorigenic HBE cells than in normal HBE cells. The decreased activity of the c-fos promoter in tumorigenic 1170I cells appeared to involve suppression through a CRE site and reduced activation by JNK-dependent pathways.
Results
We examined c-fos expression in normal, immortalized (1799 and 1198), and tumorigenic (1170I) HBE cells. cFos mRNA levels were higher in normal HBE cells than in immortalized or tumorigenic HBE cells ( Figure  1a ). Nuclear run-on analysis revealed that c-fos gene transcription was higher in normal HBE cells than in tumorigenic 1170I cells (Figure 1b) . Transient transfection assays with reporters containing the c-fos promoter from 7327 to +40 demonstrated higher promoter activity in normal HBE cells than in tumorigenic 1170I cells (Figure 1c) . These ®ndings reveal a suppression of c-fos gene transcription associated with the malignant transformation of HBE cells. Cycloheximide treatment increased basal c-fos mRNA levels in normal HBE and tumorigenic 1170I cells (data not shown), suggesting that c-fos mRNA levels were also regulated post-transcriptionally in these cells.
Binding to c-fos promoter elements within the c-fos promoter from 7327 to +40 was examined in nuclear extracts. DNaseI footprinting analysis using the 7327 to +40 fragment as a probe revealed higher binding activity in tumorigenic 1170I than in normal HBE cells, speci®cally to c-fos promoter regions that involve a CRE, ETS/SRE, SIE, and YY1 site (Figure 2 ). Binding to these response elements was examined by band shift assays, using probes to the c-fos promoter that include these elements. Binding to the CRE, YY1, ETS/SRE and SIE was greater in extracts from tumorigenic 1170I cells than in normal HBE cells (Figure 3 ). Binding was completed by excess cold wildtype but not unrelated oligonucleotides (Figure 3 ), demonstrating that binding was protein-and sequence-speci®c. These ®ndings reveal enhanced c-fos promoter binding activity associated with the malignant transformation of HBE cells. We examined the role of speci®c response elements in the regulation of c-fos promoter activity, focusing on those areas more actively bound in tumorigenic 1170I cells. Site-directed mutagenesis was performed on the cfos promoter to introduce mutations ( Figure 4a ) that were previously shown (Natesan and Gilman, 1993; Wagner et al., 1990; Johansen and Prywes, 1994) to block binding to a CRE (CREmut-fos-LUC), SRE (SREmut-fox-LUC), SIE (SIEmut-fos-LUC), or YY1 site (YY1mut-fos-LUC). In normal HBE cells, transient transfection assays revealed that the activity of c-fos promoters containing mutated SRE, SIE, CRE or YY1 sites was lower than wildtype c-fos promoter activity (Figure 4b ), suggesting that the SRE, SIE, CRE and YY1 sites were positive regulators on the cfos promoter in normal HBE cells. In tumorigenic 1170I cells, the activity of the CRE mutant c-fos promoter was greater than wildtype c-fos promoter activity, while the activity of SRE, SIE, and YY1 mutant c-fos promoters was similar to wildtype c-fos promoter activity (Figure 4b ), suggesting that the CRE was a negative regulator of the c-fos promoter in tumorigenic 1170I cells.
The activity of the SRE in the c-fos promoter is controlled by ERK-and JNK-dependent pathways, which can either activate or suppress c-fos promoter activity (Marais et al., 1993; whitmarsh et al., 1995; Janknecht and Hunter, 1997; Cavigelli et al., 1995; Gille et al., 1995; Galvin and Shi, 1997; Zinck et al., 1993) . We examined the role of these pathways in the regulation of c-fos promoter activity in normal HBE and tumorigenic 1170I cells by transiently co-transfecting fos-LUC and expression vectors containing constitutively active mutant JNK kinase (SEK)-1, MEK-1, or dominant negative mutant JNK kinase kinase (MEKK)-1 cDNAs. Similar results were observed in three separate transient co-transfection experiments, and the results of one experiment are illustrated in Figure 5 . In both normal HBE and tumorigenic 1170I cells, co-transfection of a dominant negative mutant MEKK-1 reduced, and constitutively active mutant SEK-1 activated, fos-LUC, suggesting that JNK-dependent pathways activated the c-fos promoter in these cells. Co-transfection of a constitutively active mutant MEK-1 minimally activated fos-LUC in these experiments, suggesting that MEK-1 is less potent than SEK-1 in the activation of the c-fos promoter in these cells. Figure 3 Band shift analysis was performed on nuclear extracts (10 mg per lane) prepared from normal HBE (NHBE), immortalized 1799, immortalized 1198 and tumorigenic 1170I cells using oligonucleotide probes to regions of the c-fos promoter found to be protected by DNaseI footprinting analysis. These regions contain a CRE (a), SRE (b), SIE (c), and YY1 site (d). Competition for binding to extracts from tumorigenic 1170I cells was performed using tenfold (106), 50-fold (506), or 100-fold (1006) excess wildtype (WT) or unrelated (UR) cold oligonucleotides. Small arrows point to free probe and large arrows point to shifted bands We investigated the possibility that JNK-and ERK-dependent pathways contribute to the relative c-fos levels in normal HBE and tumorigenic 1170I cells by examining JNK and ERK activities. Immune complex assays demonstrated that JNK activity was higher in normal HBE cells than in tumorigenic 1170I cells, while ERK activity was similar in normal HBE and tumorigenic 1170I cells (Figure 6a ). ERK and JNK activities in these cells were also investigated by performing transient co-transfection experiments using expression vectors containing the GAL4 DBD fused with the transcriptional activating domain of Elk-1 (Elk-GAL-DBD), which is activated most prominently by ERKs, or c-jun (Jun-GAL-DBD), which is activated by JNKs and reporter plasmids containing GAL4-response elements (GAL-UAS-LUC). Jun-GAL-DBD-induced activity was greater in normal HBE cells than in tumorigenic 1170I cells, while Elk-Gal-DBD-induced activity was similar in normal HBE and tumorigenic 1170I cells (Figure 6b ). These ®ndings demonstrated higher JNK activity in normal HBE cells than in tumorigenic 1170I cells, which correlates with relative c-fos levels in these cells.
Discussion
In this study, we examined the mechanisms that underlie the reduction in c-fos expression associated with the malignant transformation of HBE cells. Our ®ndings demonstrated a transcriptionally-mediated inhibition of c-fos expression. The activity of the cfos promoter appeared to be suppressed through increased binding to a CRE site and through reduced activation by JNK-dependent pathways. Post-transcriptional mechanisms also contributed to the suppression of c-fos expression in tumorigenic 1170I cells, as cycloheximide treatment increased basal c-fos levels in these cells. Similarly, previous studies have shown that c-fos mRNA levels are regulated both transcriptionally and post-transcriptionally in response to a number of extra-cellular stimuli (Cohen and Curran, 1989) . However, this is the ®rst demonstration that these mechanisms are also active during the process of malignant transformation.
The suppression of c-fos gene transcription in tumorigenic 1170I cells was associated with reduced transcriptional activity of the c-fos promoter from 7327 to +40 and increased binding to response elements within this region, including a CRE, SIE, ETS/SRE, and YY1 site. Therefore, the transcriptional activity of the c-fos promoter correlated inversely with binding to these response elements. One possible explanation for this inverse relationship is that one or more of these response elements functioned as a transcriptional suppressor of the c-fos promoter in tumorigenic 1170I cells. Previous studies have shown that the regulatory role of speci®c elements in the c-fos promoter depends upon complex interactions of these elements with transcription factors. The SRE can act as a positive or negative regulatory element depending on the phosphorylation state of the ternary complex (Zinck et al., 1993) . Interactions between ATF/CREB and YY1, which binds to a YY1 site adjacent to the CRE in the c-fos promoter, can convert the CRE from a transcriptional activator to a transcriptional suppressor (Natesan and Gilman, 1993; Galvin and Shi, 1997) . We found evidence that mutating the CRE decreased cfos promoter activity in normal HBE cells and increased c-fos promoter activity in tumorigenic 1170I cells, suggesting that the CRE functioned as a positive regulatory element in normal HBE cells and a negative regulatory element in tumorigenic 1170I cells. This could be accounted for by dierences in CREBP phosphorylation or by dierent co-activators/repressors associated with CREBP in these cells. YY1 sites in the c-fos promoter adjacent to SRE and CRE sites have demonstrated positive and negative regulatory eects through interactions of YY1 with proteins bound to these response elements (Natesan and Gilman, 1993 Gilman, ,1995 Gualberto et al., 1992) . A YY1 site distinct from the ones adjacent to the SRE and CRE was actively bound in tumorigenic 1170I cells, and the role of this YY1 site has not been examined previously. Mutation of this site reduced c-fos promoter activity in normal HBE cells, suggesting that this YY1 site was a positive regulatory element in normal HBE cells.
We investigated the role of MAP kinase pathways in maintaining the relative levels of c-fos expression in these cells. The c-fos promoter was activated by cotransfection of a constitutively active JNK kinase (SEK)-1 and inhibited by a dominant negative JNK kinase kinase (MEKK)-1, demonstrating a role for JNK-dependent pathways in the activation of the c-fos promoter, which corroborates the results of previous studies in other cell types. (Whitmarsh et al., 1995; Janknecht and Hunter, 1997; Cavigelli et al., 1995) . JNK activity was lower in tumorigenic 1170I cells than in normal HBE cells, which is consistent with the relative levels of c-fos mRNA in these cells, supporting the possibility that JNK-dependent pathways contributed to the reduction in c-fos expression associated with malignant transformation. JNK-dependent pathways activate the SRE in the c-fos promoter through phosphorylation of the ternary complex factors Elk-1 and SAP-1a, which stimulates ternary complex DNAbinding activity (Whitmarsh et al., 1995; Janknecht and Hunter, 1997; Cavigelli et al., 1995) . SRE-binding activity correlated inversely with JNK activity in these cells, suggesting that kinases other than JNK stimulated ternary complex DNA-binding activity in tumorigenic 1170I cells. In addition to JNKs, ERKs and Rho-dependent signaling pathways activate ternary complex DNA-binding activity (Gille et al., 1995; Hill et al., 1995) .
MAP kinase pathways and the genes that they regulate, including c-fos, are integral components of receptor tyrosine kinase pathways. Speci®c receptor tyrosine kinases are activated during the malignant transformation of HBE cells, as demonstrated by the high expression of EGF receptor and its ligands in lung cancer cells (Sobol et al., 1987; Rusch et al., 1997) . Inhibition of EGF receptor activity with blocking antibodies to TGF-a suppresses lung cancer cell growth (Putnam et al., 1992) . Further, blockade of receptor tyrosine kinases alone has anti-tumor eects and can act synergistically in combination with conventional Immune complex assays (a) were performed on normal HBE (NHBE) and tumorigenic 1170I cells using myelin basic protein (MBP) to examine ERK activity and GST-jun (G-cJ) to examine JNK activity. Transient co-transfection assays (b) were performed on normal HBE and tumorigenic 1170I cells using 0.5 mg of reporter plasmid containing GAL4 response elements (GAL-UAS-LUC) and 0.5 mg of expression vector containing the GAL4 DBD fused to the transactivation domain of Elk-1 (Elk-GAL-DBD) or c-jun (jun-GAL-DBD) or the GAL4 DBD alone (GAL-DBD). Luciferase activities were expressed as the mean and standard deviation of ®ve identical wells, were normalized to cell number (10 5 cells per well), and were corrected for dierences in transfection eciency by determining relative levels of bgalactosidase expression following transfection of a b-galactosidase expression vector under the control of the b-actin promoter chemotherapeutic agents (Baselga et al., 1996; Fan et al., 1993 
Materials and methods

Cell lines
Normal, immortalized, and tumorigenic HBE cells were used in these studies. Normal HBE cells were grown as primary, senescent cultures from bronchial mucosal biopsies as previously described (Kim et al., 1995) . Immortalized and tumorigenic HBE cell lines were obtained from Dr Andres Klein-Szanto, Fox Chase Cancer Center, Philadelphia, PA (Klein-Szanto et al., 1992) . Immortalized HBE cells are non-tumorigenic in nude mice, and tumorigenic HBE cells are tumorigenic. These cell lines were derived from a single cell subclone of the BEAS-2B cell line, which is an HBE cell immortalized with a hybrid Adenovirus/Simian Virus 40 (Reddel et al., 1988) . To develop the immortalized and tumorigenic HBE cell lines, BEAS-2B cells were inserted into rat tracheas that had been denuded of bronchial epithelium along with beeswax pellets containing either cigarette smoke condensate (CSC) or no treatment. The tracheas were placed subcutaenously in nude mice. Tumors developed 6 months later. Cell lines were derived from the tumors, and these cell lines exhibited varying tumorigenicity in nude mice. 1799 is a non-tumorigenic cell line derived from BEAS-2B cells exposed to a beeswax pellet alone. Cell lines derived from BEAS-2B cells exposed to CSC include the 1198 cell line, which is non-tumorigenic, and the 1170I cell line, which is tumorigenic. Tumorigenic 1170I cells exhibit an adenocarcinoma appearance.
Cell growth conditions
Normal HBE cells were grown in Keratinocyte Serum-Free Media (KSFM) (GIBCO/BRL, Gaithersburg, MD) plus bovine pituitary extract and epidermal growth factor (EGF) as previously described (Kim et al., 1995) . Immortalized 1799 cells were grown in the same conditions as normal HBE cells. Immortalized 1198 and tumorigenic 1170I cells were grown in KSFM plus 3% fetal calf serum.
Northern analysis
Total cellular RNA was prepared from 10 6 cells per 10 cm plate as previously described (Kim et al., 1995) . RNA was subjected to electrophoresis (20 mg per lane) on a 1% agarose gel containing 2% formaldehyde, transferred to a nylon membrane (Duralon UV, Stratagene, La Jolla, CA), hybridized to an a-32 P-dCTP-labelled cDNA probe, washed in high stringency conditions, and autoradiographed for 24 ± 48 h. The human c-fos cDNA probe used in this study was a gift from Dr Je Holt (Vanderbilt University, Nashville, TN).
Band shift assays
Nuclear extracts were prepared as previously described (Kim et al., 1995) . Nuclear extracts (2 mg) were preincubated with 2 mg of poly(dI-dC) for 15 min at 48C and then incubated with labeled oligonucleotide DNA (6000 c.p.m.) for 15 min at 48C in the presence of 10 mM Tris-HCl (pH 7.5), 10 mM, 1 mM EDTA, 20% glycerol, 1 mM dithiothreitol and 5 mM MgCl 2 . c-Fos promoter oligonucleotides containing SRE, CRE, SIE, and YY1 sequences were commercially prepared (Operon Technologies, Inc., Alameda, CA.) and were the following (consensus-binding sequences are in bold): ETS/SRE: 5' -CTTACAC-AGGATGTCCATATTAGGACATCTGCG -TCA-3' and 3'-GAATGTGTCCTACAGGTATAATCCTGTAGACGC-AGT-5'; CRE: 5'-CCACCGTGGTTGAGCCTGACGTT-TACACTCATTC-3' and 3'-GGTGGCACCAACTCGGG-CACTGCAAATGTGAGTAAG-5'; SIE: 5'-GCAGCCCG-CGAGCAGTTCCCGTCAATCCCTCCCC -CC-3' and 3'-CGTCGGGCGCTCGTCAAGGGCAGTT'; YY1: 5'-GT-AGCC CTGGGGGGAGCCATCCCCGAAACCCCTC -3' and 3'-CATCGGGACCCCCCTCGGTAGGGGCTTTG-GGGAG-5'. Oligonucleotides were end-labeled with g-32 P-ATP (4000 mCi/mol) using T 4 polynucleotide kinase (Boehringer-Mannheim, Indianapolis, IN) and puri®ed by ethanol precipitation. For competition experiments, excess nonradioactive oligomers (consensus or unrelated) were added prior to the addition of radioactive oligomers. The reaction mixture was subjected to electrophoresis on a 5% nondenaturing polyacrylamide gel. The gel was then dried and autoradiographed using an amplifying screen at 7808C.
DNaseI footprinting analysis
The c-fos promoter fragment from 7327 to +40 was 5' end-labelled with g 32 P-ATP. Binding reactions were performed with nuclear extracts using a range of proteins concentrations and 0.25 ng probe in the presence of 1 mM CaCl 2 , 1 mM Tris-HCl (pH 7.5), 5 mM NaCl, 0.1 mM EDTA, 5% glycerol, and 1 mM dithiothreitol at 308C for 30 min. The binding reactions were treated with DNaseI (Worthington DPRF) at RT for 2 min, made 20 mM EDTA, extracted with phenol/chloroform, precipitated in sodium acetate/ethanol, loaded onto a 4% polyacrylamide gel, electrophoresed, dried and autoradiographed.
Transient transfection assays
In six well dishes, 10 5 cells per well were transfected with luciferase reporter plasmid and expression vectors for 6 h using lipofectamine (GIBCO ± BRL). The transfectant solution was removed and the cells were placed in media for 24 h. The cells were then subjected to luciferase assays as previously described (Kim et al., 1995) . Luciferase activities were expressed as the mean and standard deviation of ®ve identical wells. Luciferase values were normalized to cell number (10 5 cells per well). For comparisons between cell lines, luciferase values were corrected for dierences in transfection eciency by relative levels of b-galactosidase expression following transfection of a b-galactosidase expression vector under the control of the b-actin promoter (Gunning et al., 1987) . b-galactosidase assays were performed using the Galactolight Plus Reporter System (Tropix, Inc., Bedford, MA) according to the manufacturer's instructions.
Expression vectors and reporter plasmids
The constitutively active mutant cDNAs for SEK-1 (ED mutant, under the control of the elongation factor promoter) and MEK-1 (R4F mutant, under the control of the CMV promoter) were gifts from Dr John M Kyriakis (Harvard Medical School, Boston, MA) and Dr Natalie G Ahn (University of Colorado, Boulder, CO), respectively (Sanchez et al., 1994; Mansour et al., 1996) . The dominant negative mutant cDNA for MEKK-1 under the control of the SV40 promoter was a gift from Dr FX Claret (University of California-San Diego, San Diego, CA) (Minden et al., 1995) . Other SV40-driven expression vectors were purchased; these contained the DNA-binding domain of GAL-4 alone (GAL-DBD) or fused to the transcriptional activation domain of Elk-1 (Elk-GAL-DBD) or c-jun (JUN-GAL-DBD) (Stratagene, Inc). GAL-UAS-LUC is a luciferase reporter plasmid containing ®ve repeats of the GAL4 binding element (Stratagene, Inc.).
The c-fos promoter from 7327 to +40 (a PstI ± PstI genomic fragment) (Whaley et al., 1995) was subcloned in sense (fos-LUC) and anti-sense (sof-LUC) orientation into the pGL3-basic luciferase reporter plasmid (Promega Inc., Madison, WI). Mutations were created in speci®c c-fos promoter elements using the Quikchange Kit (Stratagene, Inc.). The mutations created in fos-LUC were based on mutations previously shown to disrupt binding of transcription factors to their cognate response elements (Natesan and Gilman, 1993; Wagner et al., 1990; Johansen and Prywes, 1994) . The PCR primers used to create these mutations were the following (the mutations are underlined): SREmut-fos-LUC: 5'-CTTACACAGGATGTCCCAATCGGGACATC-3' and 3'-GAATGTGTCCTACAGGGTTAGCCCTGTAG-5'; CREmut-fos-LUC:
5'-CCACCGTGGTTGAGCGCGTCA GCTTTACACTCATTC-3' and 3'-GGTGGCACCAACT-CGCGCAGTCGAAATGTGAGTAAG-5'; SIEmut-fos-Luc: 5 '-GCAGCCCGCGAGCAGATCACCTCAATCCCTCCCC CC-3' and 3'-CGTCGGGCGCTCGTCTAGTGGAGTT-AGGGAGGGGGG-5'; YY1mut-fos-LUC: 5'GTAGCC-CTGGGGGGAGAGTTCCCCGAAACCCCTC-3' and 3'-CATCGGGACCCCCCTCTCTCAAGGGGCTTTGGGGA-G-5'. The presence of the indicated mutations in the PCR products was con®rmed by DNA sequencing.
JNK and ERK assays
10
7 normal HBE or tumorigenic 1170I cells were harvested in WCEB buer (25 mM HEPES pH 7.7, 0.3 mM NaCl, 15 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton X, 10 mM dithiothreitol (DTT), 0.25 mM sodium vanadate, 10 mg/ mL aprotinin, 10 mg/mL leupeptin, 2 mg/mL pepstatin, and 1 mM benzamidine), rotated at 48C for 20 min and centrifuged to pelletize cell debris. JNK-1 or ERK-1 and -2 were immunoprecipitated from 100 mg of cell extract diluted in 200 mL WCEB and 600 mL HBB buer (20 mM HEPES pH 7.7, 50 mM NaCl, 0.1 mM EDTA, 2.5 mM MgCl 2 , 0.05% Triton X and phosphatase inhibitors) by adding goat antibodies that recognize JNK-1 or ERK-1 and -2 (Santa Cruz Biotechnology, Santa Cruz, CA), rotated at 48C for 2 h and immunoprecipitated with 20 mL protein G and A agarose beads. The beads were washed several times in ice cold HBB and centrifuged. The immunoprecipitated proteins were resuspended in kinase buer (20 mM HEPES, pH 7.5, 20 mM glycerol phosphate, 10 mM PNPP, 10 mM MgCl 2 , 10 mM dithiothreitol, 50 mM sodium vanadate, 20 mM ATP and 0.1 mM [w 32 P]ATP (2000 c.p.m/pmol)) and 2 mg of GST-cjun (1-79) (Santa Cruz Biotechnology) or myelin basic protein (Santa Cruz Biotechnology) were added. The kinase reaction was performed at 308C for 20 min. The beads were suspended in Laemmli buer, boiled for 5 min, and the samples were electrophoresed on acrylamide-SDS gels and autoradiographed.
Nuclear run-on analysis
Nuclei were prepared from the cells by lysis in hypotonic buer (0.8% NP-40, 10 mM HEPES, pH 7.9, 10 mM KCl, 0.75 M spermidine, 0.15 M spermine, 0.1 mM EDTA, pH 8.0, 0.1 mM EGTA, 10 mM DTT), douncing on ice and centrifugation at 1500 r.p.m. The pellets (nuclei) were resuspended thoroughly in transcription buer (150 mM KCl, 5 mM MgCl 2 , 1 mM MnCl, 20 mM HEPES, pH 7.9, 10% glycerol). Radioactive RNA was synthesized from the nuclei by adding the nucleotide mix (transcription buer containing 5 mM DTT, 1 mM ATP, 1 mM GTP, 1 mM CTP, 250 mCi [a 32 P]UTP) and incubating at 258C for 30 min. The nuclei were centrifuged at 1500 r.p.m. for 6 min, resuspended in DNase I buer (2 mM Tris, pH 7.5, 5 mM MgCl 2 ), and treated with 5 mL DNase I at RT for 10 min to digest genomic DNA. Nuclear protein was digested by the addition of 5 mL proteinase K, 500 mL 1% SDS/16TE, 10 mL 0.5 M EDTA and 240 mL 16TE and incubation at 408C for 30 min. RNA was prepared from the nuclear lysates by phenol/chloroform extraction, NH 3 OAc/EtOH precipitation overnight at 7208C, centrifugation at 14 000 r.p.m. for 10 min at 48C, resuspension of the pellet in DNase I buer and DNase I digestion as described above. Proteinase K treatment was repeated followed by phenol/chloroform extraction, NH 3 OAc/EtOH precipitation. The RNA pellet was resuspended in water, and incorporation of 32 P was quantitated with a scintillation counter. The c-fos and GAPDH cDNAs and the c-fos expression vector with no insert (negative control) were immobilized on nylon membranes (5 mg/mm 2 ) by slot blot and prehybridized (56SSPE, 56Denhardt's Solution, 0.5% SDS, 50% deionized formamide, 200 mg/mL tRNA and 500 mg/mL ss DNA) at 428C for 2 h. The RNA was boiled for 3 min, chilled on ice, added to hybridization solution (the same as the prehybridization solution) in sucient quantity to cover the slot-blot membrane at a concentration of 6.6610 7 c.p.m./mL, and incubated at 428C for 48 h. The membranes were washed to a stringency of 0.16SSC, 1% SDS at 658C and autoradiographed.
